Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elvire Pons

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2025
Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 StudyJacob Sands, Myung-Ju Ahn, Aaron Lisberg, et al.
Annals of Surgery|February 3, 2021
Early Locoregional Breast Surgery and Survival in de novo Metastatic Breast Cancer in the Multicenter National ESME CohortJudicaël Hotton, Amélie Lusque, Léa Leufflen, et al.
Clinical and Translational Science|February 16, 2024
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumorsDebbie Robbrecht, Jean-Jacques Grob, Oliver Bechter, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 14, 2020
Radiation therapy to the primary tumor for de novo metastatic breast cancer and overall survival in a retrospective multicenter cohort analysisElvire Pons-Tostivint, Youlia Kirova, Amélie Lusque, et al.
EMBO Molecular Medicine|May 25, 2021
Pancreatic cancer intrinsic PI3Kα activity accelerates metastasis and rewires macrophage componentBenoit Thibault, Fernanda Ramos-Delgado, Elvire Pons-Tostivint, et al.
Annals of Surgical Oncology|December 13, 2018
Survival Impact of Locoregional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancers in a Large Multicentric Cohort Study: A Propensity Score-Matched AnalysisElvire Pons-Tostivint, Youlia Kirova, Amélie Lusque, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 14, 2025
A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLCMyung-Ju Ahn, Aaron Lisberg, Yasushi Goto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2023
Trastuzumab Deruxtecan in Patients With <i>HER2</i>-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 TrialKoichi Goto, Yasushi Goto, Toshio Kubo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2024
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 StudyMyung-Ju Ahn, Kentaro Tanaka, Luis Paz-Ares, et al.
Frontiers in Immunology|March 20, 2026
PD-1 blockade does not enhance alloimmunization after allogeneic dendritic cell vaccination in cancer patientsSeverine Planel, Guillaume Vayssière, Gianni Maggipinto, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2025
Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 StudyJacob Sands, Myung-Ju Ahn, Aaron Lisberg, et al.
Annals of Surgery|February 3, 2021
Early Locoregional Breast Surgery and Survival in de novo Metastatic Breast Cancer in the Multicenter National ESME CohortJudicaël Hotton, Amélie Lusque, Léa Leufflen, et al.
Clinical and Translational Science|February 16, 2024
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumorsDebbie Robbrecht, Jean-Jacques Grob, Oliver Bechter, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 14, 2020
Radiation therapy to the primary tumor for de novo metastatic breast cancer and overall survival in a retrospective multicenter cohort analysisElvire Pons-Tostivint, Youlia Kirova, Amélie Lusque, et al.
EMBO Molecular Medicine|May 25, 2021
Pancreatic cancer intrinsic PI3Kα activity accelerates metastasis and rewires macrophage componentBenoit Thibault, Fernanda Ramos-Delgado, Elvire Pons-Tostivint, et al.
Annals of Surgical Oncology|December 13, 2018
Survival Impact of Locoregional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancers in a Large Multicentric Cohort Study: A Propensity Score-Matched AnalysisElvire Pons-Tostivint, Youlia Kirova, Amélie Lusque, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 14, 2025
A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLCMyung-Ju Ahn, Aaron Lisberg, Yasushi Goto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2023
Trastuzumab Deruxtecan in Patients With <i>HER2</i>-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 TrialKoichi Goto, Yasushi Goto, Toshio Kubo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2024
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 StudyMyung-Ju Ahn, Kentaro Tanaka, Luis Paz-Ares, et al.
Frontiers in Immunology|March 20, 2026
PD-1 blockade does not enhance alloimmunization after allogeneic dendritic cell vaccination in cancer patientsSeverine Planel, Guillaume Vayssière, Gianni Maggipinto, et al.
Pageof 6